Epion Therapeutics key facts
as of Oct 2026- Provider of medical devices designed to develop an innovative treatment for an ectatic corneal disease that can bring early intervention.
- Epion Therapeutics is valued at approximately $55.5M as of Oct 2026 (last reported valuation).
- It has raised $59.2M; the latest was Later Stage VC ($18.5M) in Sep 2025.
- Notable investors include AXA Investment Managers, 7G Bioventures, New World Angels.
- Status: Privately Held (backing).
Epion Therapeutics's last reported valuation, Sep 2022. Nothing priced has surfaced since.
- ·Watch Epion Therapeutics: the Monday email on marks, rounds and moves
Epion Therapeutics funding rounds
No funding rounds for Epion Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Epion Therapeutics
3Epion Therapeutics valuation
Epion Therapeutics's last reported valuation was $55.5 million in Sep 2022. No priced round, secondary trade or fund mark has surfaced since.
Epion Therapeutics investors
3 investors are on record for Epion Therapeutics, including AXA Investment Managers, 7G Bioventures and New World Angels.
About Epion Therapeutics
Provider of medical devices designed to develop an innovative treatment for an ectatic corneal disease that can bring early intervention. The company's devices help to overcome the weakened cornea, the proteins that make up the cornea can be strengthened by chemically cross-linking them and treat keratoconus without disrupting the epithelium, enabling patients to avail of enhanced vision that is available in a wide range for the treatment of eye diseases.
- Sector
- Healthcare
- HQ
- Burlington, MA, United States
- Founded
- 2012
- Employees
- 5
- Website
- epiontx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.